Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18944013 | 0.83 | TDP1 (0.39) | ULK1CDK9CSF1RBRD4 | |
| SCHEMBL18944015 | 0.82 | CDK9 (0.38) | ULK1CCNT1CDK9BTKBRD4 | |
| SCHEMBL20034121 | 0.81 | CDK9 (0.42) | ULK1CCNT1CDK9 | |
| SCHEMBL18944018 | 0.80 | ULK1 (0.45) | ULK1CCNT1CDK9PIK3CGBRD4 | |
| SCHEMBL18944010 | 0.78 | BRD4 (0.51) | ULK1PIK3CGBRD4 | |
| SCHEMBL18944017 | 0.76 | ULK1 (0.44) | ULK1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL18944012 | 0.76 | CCNB2 (0.46) | ULK1PIK3CGBRD4 | |
| SCHEMBL18944014 | 0.76 | ULK1 (0.42) | ULK1BTKPIK3CGBRD4 | |
| SCHEMBL18944135 | 0.74 | ULK1 (0.55) | ULK1BTK | |
| SCHEMBL18944011 | 0.74 | FYN (0.43) | ULK1PIK3CGBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP3K13, WEE2 | ULK1 495/4885PIK3CD 256/4885PIK3CA 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.